Siegel CA - Search Results

1

Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.

Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. Siegel CA, et al. Among authors: siegel ls. Inflamm Bowel Dis. 2011 Jan;17(1):30-8. doi: 10.1002/ibd.21386. Epub 2010 Sep 1. Inflamm Bowel Dis. 2011. PMID: 20812335 Free PMC article.

2

Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies.

Courville EL, Siegel CA, Vay T, Wilcox AR, Suriawinata AA, Srivastava A. Courville EL, et al. Among authors: siegel ca. Am J Surg Pathol. 2009 Sep;33(9):1341-7. doi: 10.1097/PAS.0b013e3181ad25b6. Am J Surg Pathol. 2009. PMID: 19606015

3

A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match?

Wilcox AR, Dragnev MC, Darcey CJ, Siegel CA. Wilcox AR, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2010 Apr;16(4):645-50. doi: 10.1002/ibd.21094. Inflamm Bowel Dis. 2010. PMID: 19714751 Free PMC article.

4

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.

Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. Siegel CA, et al. Inflamm Bowel Dis. 2010 Oct;16(10):1658-62. doi: 10.1002/ibd.21233. Inflamm Bowel Dis. 2010. PMID: 20186940 Free PMC article.

5

Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy.

Siegel CA. Siegel CA. Inflamm Bowel Dis. 2010 Dec;16(12):2168-72. doi: 10.1002/ibd.21305. Inflamm Bowel Dis. 2010. PMID: 20848508 Free PMC article. Review.

6

Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.

Johnson FR, Hauber B, Özdemir S, Siegel CA, Hass S, Sands BE. Johnson FR, et al. Among authors: siegel ca. J Manag Care Pharm. 2010 Oct;16(8):616-28. doi: 10.18553/jmcp.2010.16.8.616. J Manag Care Pharm. 2010. PMID: 20866166 Free PMC article.

7

What options do we have for induction therapy for Crohn's disease?

Siegel CA. Siegel CA. Dig Dis. 2010;28(3):543-7. doi: 10.1159/000320414. Epub 2010 Sep 30. Dig Dis. 2010. PMID: 20926884 Free PMC article.

8

Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.

Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Ashworth LA, et al. Inflamm Bowel Dis. 2012 May;18(5):838-43. doi: 10.1002/ibd.21844. Epub 2011 Sep 1. Inflamm Bowel Dis. 2012. PMID: 21887728 Clinical Trial.

9

Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Siegel CA, et al. Clin Gastroenterol Hepatol. 2012 Jan;10(1):46-51. doi: 10.1016/j.cgh.2011.09.017. Epub 2011 Oct 1. Clin Gastroenterol Hepatol. 2012. PMID: 21963958 Free PMC article.

10

Do inflammatory bowel disease therapies cause cancer?

Mason M, Siegel CA. Mason M, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2013 May;19(6):1306-21. doi: 10.1097/MIB.0b013e3182807618. Inflamm Bowel Dis. 2013. PMID: 23470503 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

220 results

Search Page